Synthetic DNA producer DNA Script and personalised health plan provider Transcarent each closed $200m corporate-backed series C rounds.

Funding: France-based synthetic DNA producer DNA Script has completed a $200m series C round featuring pharmaceutical firm Merck Group, genomics technology provider Illumina, laboratory equipment maker Agilent, life sciences real estate investment trust Alexandria Real Estate Equities and conglomerate Danaher. The latest tranche included Healthcor Management, EureKare, Irving Investors and accounts and funds advised by…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.